Marvell Stock Takes Two Hits in One Morning: Both Blame the Lumentum Deal

Marvell Technology Inc. (NASDAQ:MRVL) has just struck one of the largest chip deals on record: buying Lumentum Holdings Inc. (NASDAQ:LITE) in an all-stock transaction valued at $115 billion.

On Tuesday, two of Wall Street’s most-followed chip analysts cut their calls on Marvell stock for the same reason.

Bank of America Global Research downgraded Marvell to Neutral from Buy and cut its price target to $225 from $400. Cantor Fitzgerald kept its Neutral rating but lowered its target to $225 from $350.

Marvell shares rose 2.4% to $175.60 on Tuesday morning. Even so, they lost 31.9% over the previous three sessions, their worst three-day stretch since October 2000.

That slide has erased about $66 billion in market value.

So what turned two of Wall Street’s top chip analysts cautious on a stock that has still doubled this year?

Bank of America Sees Dilution Through 2030

Vivek Arya has no quarrel with the logic. Lumentum adds lasers, optical circuit switches and scarce indium phosphide manufacturing to Marvell’s signal-processing and switching franchise.

His problem is the math.

According to Arya, about $1 billion in cost cuts is not enough to offset a roughly 50% increase in Marvell’s share count.

Bank of America modeled the combined company on consensus estimates. With no revenue synergies, earnings per share would come in 4.9% below standalone Marvell in calendar 2028, 10.5% below in 2029 and 14.7% below in 2030.

That runs against management’s promise of a deal that adds to adjusted earnings in its first year after closing.

The surprise itself is part of the problem.

"The news comes as a considerable surprise," Arya said in a note late Monday. Marvell had made no mention of large acquisitions at its analyst day last month.

His $225 target is based on 20 times calendar 2028 earnings including stock compensation, down from 33 times.

Cantor Sees Modest Accretion, but No Reason to Buy

C.J. Muse reached the same $225 by a different route.

His combined model shows calendar 2028 adjusted earnings of $12.55 a share, slightly above $12.50 for Marvell alone. He also believes the $1 billion synergy target is conservative.

On paper, the deal works. In the market, it parks the stock.

Only four weeks ago, according to Muse, investors found Marvell’s story compelling. Now the shares sit "in deal purgatory for at least the next 5-7 quarters," Muse said in a note late Monday.

He also questioned why Lumentum is selling at this point in the optical cycle. Meanwhile, rivals have time to win business: customers could qualify lasers from Coherent Corp. (NYSE:COHR) or shift chip orders to Broadcom Inc. (NASDAQ:AVGO).

Muse’s target reflects 18 times pro forma calendar 2028 earnings.

Marvell’s Answer: Move First

Management sees the risk differently. In its view, the shift from copper to optics inside AI data centers rewards whoever gets there first.

"The companies that move first and help define this transition will set the standard for decades to come," Marvell CEO Matt Murphy said in the deal announcement.

Lumentum CEO Michael Hurlston made the same case to his staff.

"I have said repeatedly that we see optics and electronics beginning to collide," Hurlston said in a message filed with the Securities and Exchange Commission.

China Holds the Stopwatch

The companies expect the deal to close in the first half of 2028, and China’s approval is the biggest unknown.

Walking away would be expensive. According to Cantor, Marvell would owe a $3.2 billion reverse termination fee if regulators block the deal.

The market is already pricing that doubt.

At 4.5 Marvell shares per Lumentum share, the offer is now worth about $790 per Lumentum share, roughly 30% below its $1,132 headline value. Lumentum traded at $704.71 on Tuesday, about 11% below even that.

Most of Wall Street Is Still Bullish

Needham, Rosenblatt and Susquehanna all kept bullish ratings with $300 targets.

According to Benzinga Analyst Ratings, 25 of the 27 analysts covering Marvell rate it a Buy and two rate it a Hold, with an average price target of $310, about 76% above Tuesday’s price.

Bank of America thinks the deal costs shareholders earnings. Cantor thinks it adds a little.

Both would rather wait for China than find out.

Image: Shutterstock